Key Definitions
- Ferritin: Iron storage protein; levels <30 ng/mL indicate depleted stores even with normal hemoglobin. Cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.
- Tyrosine hydroxylase (TH): Enzyme converting L-tyrosine to L-DOPA; requires iron as cofactor. Rate-limiting step in catecholamine (dopamine, norepinephrine) production.
- DAT (Dopamine transporter): Membrane protein that clears dopamine from the synapse. Zinc blocks DAT at an extracellular site, increasing synaptic dopamine.
- SCFA (Short-chain fatty acids): Bacterial metabolites (butyrate, propionate, acetate) produced from fiber fermentation; influence brain function via gut-brain axis.
- Non-responder: Individual showing <10% improvement despite adequate supplementation; may have genetic variants affecting nutrient metabolism or already-optimal baseline levels.
- Adjunctive therapy: Supplement used alongside (not instead of) standard ADHD treatment (medication, behavioral therapy).
Key Findings
Our analysis of 28 primary sources reveals the following core findings, each drawn from peer-reviewed evidence with effect sizes and confidence intervals where available:
- 84% of ADHD children have ferritin <30 ng/mL versus normal controls at 44 ng/mL; ferritin inversely correlates with ADHD severity (r = −0.34) (Konofal et al., 2004)
- Vitamin D is 6.55 ng/mL lower in ADHD vs. controls (P < .001), with OR 1.97 for ADHD in deficient individuals (2025 meta-analysis)
- Zinc supplementation reduces ADHD total scores (SMD: −0.62, P = .04) across 6 RCTs with 489 children (Talebi et al., 2022)
- Omega-3 requires ≥4 months for significant effect (SMD: −0.35, P = .007); shorter durations show no benefit (Chang et al., 2023)
- Magnesium L-threonate is the only form with ADHD-specific trial data; 47% response rate in pilot study (Surman et al., 2021)
- L-tyrosine develops tolerance within 6 weeks — all 8 initial responders lost benefit (Reimherr et al., 1987)
- Czech-specific: Only 19.2% of Czech youth have sufficient vitamin D (≥75 nmol/L); 51.5% never supplement (Holmannová et al., 2025)
Frequently Asked Questions
Which single supplement has the strongest evidence for ADHD in adults?
Iron (ferritin optimization) has the most robust evidence for adult ADHD where a deficiency exists. Studies show 84% of ADHD children have ferritin below 30 ng/mL, and ferritin inversely correlates with symptom severity (r = −0.34, Konofal et al., 2004). Target ferritin >50 ng/mL via iron bisglycinate (25-65mg elemental). Critically, this only helps if a deficiency is present — screen first with serum ferritin and transferrin saturation before supplementing.
Do supplements work as well as stimulant medication?
No. Stimulants (methylphenidate, lisdexamfetamine) produce effect sizes of approximately SMD 0.7-1.0 for core ADHD symptoms; supplementation of measured deficiencies produces SMD 0.3-0.6. Supplements are adjuncts to evidence-based treatment, not replacements. The one scenario where supplementation shows comparable effect is severe iron deficiency, where repletion alone may reduce symptoms substantially.
Why does omega-3 require 4+ months to work?
Omega-3 incorporates into neuronal membrane phospholipids over 3-4 months, reaching steady-state concentrations that alter membrane fluidity and neurotransmitter receptor function. The Chang et al. (2023) meta-analysis shows SMD −0.35 only with intervention durations ≥4 months; shorter trials show null effects not because omega-3 fails but because tissue concentrations have not yet changed. Target EPA-dominant formulas (EPA:DHA ≥2:1) at 1-2g EPA daily.
Should I supplement everything on this list at once?
No. Our protocol uses a sequential approach: test biomarkers first (ferritin, 25-OH vitamin D, CBC, magnesium RBC), supplement only measured deficiencies for 8-12 weeks, then reassess. Stacking untested supplements obscures which intervention works and increases risk of interactions (e.g., zinc-copper competition, high-dose iron GI effects). Cost-effectiveness also favors targeted repletion.
Methodology Note
This protocol synthesizes findings from 28 primary sources including meta-analyses on iron (Tseng et al., 2018), vitamin D (2025 meta-analysis), zinc (Talebi et al., 2022), and omega-3 (Chang et al., 2023), alongside RCTs on specific interventions. We prioritized supplements with established mechanisms in dopamine synthesis and meta-analytic evidence. L-tyrosine was included specifically to document lack of evidence. Full methodology: /methodology
Table of Contents
- The Hierarchy
- Tier 1: Screen First (Iron, Vitamin D)
- Tier 2: Evidence-Based Adjuncts (Zinc, Magnesium)
- Tier 3: Conditional (Omega-3)
- What Doesn’t Work
- Protocol Summary
- Comparison Tables
- Limitations & Caveats
- Related Topics
- Sources
The Evidence Hierarchy {#hierarchy}
Not all ADHD supplements are equal. As of April 2026, evidence sorts into clear tiers:
| Tier | Action | Supplements |
|---|---|---|
| 1: Screen First | Test → supplement if deficient | Iron (ferritin), Vitamin D |
| 2: Evidence-Based Adjunct | Consider alongside medication | Zinc, Magnesium |
| 3: Conditional | May help specific subgroups | Omega-3 (≥4 months only) |
| 4: No Evidence | Skip these | L-tyrosine, creatine (for ADHD specifically) |
The critical insight: ADHD supplement response depends on baseline deficiency status. Supplementing someone with adequate ferritin is unlikely to help; supplementing someone at 18 ng/mL may be transformative.
Tier 1: Screen First {#tier-1}
Iron (Ferritin): The Most Actionable Biomarker
Why ferritin matters for ADHD:
Iron is a required cofactor for tyrosine hydroxylase — the enzyme that converts tyrosine to L-DOPA, the rate-limiting step in dopamine synthesis. Low iron = impaired dopamine production at the enzymatic level.
The evidence is striking:
Konofal et al. (2004, Archives of Pediatrics & Adolescent Medicine) found:
- Mean ferritin in ADHD children: 23 ng/mL
- Mean ferritin in controls: 44 ng/mL (P < .001)
- 84% of ADHD children below 30 ng/mL
- Ferritin inversely correlated with ADHD severity (r = −0.34)
Tseng et al. (2018, Scientific Reports) meta-analyzed 17 articles:
- ADHD individuals have significantly lower ferritin (Hedges’ g = −0.246)
- Iron-deficient ADHD shows dramatically higher symptom severity (Hedges’ g = 0.888)
Target levels:
| Level | Interpretation |
|---|---|
| <30 ng/mL | Depleted stores — supplement indicated |
| 30–50 ng/mL | Suboptimal for brain function — consider supplementation |
| >50 ng/mL | Adequate — no supplementation needed |
| >100 ng/mL | Upper limit for supplementation |
Protocol if deficient:
- Form: Ferrous bisglycinate (better tolerated) or ferrous sulfate (cheaper, more GI effects)
- Dose: 18–65 mg elemental iron/day depending on severity
- Timing: Away from calcium, coffee, tea; with vitamin C to enhance absorption
- Retest: After 3 months
⚠ Important: Iron overload is harmful. Do NOT supplement without testing ferritin first. Normal hemoglobin does not rule out low ferritin.
Vitamin D: Strong Association, Czech Epidemic
The mechanism:
Vitamin D regulates expression of tyrosine hydroxylase (Cui et al., 2015, Neuroscience), directly linking it to dopamine synthesis. It also modulates over 200 genes involved in brain development and neurotransmission.
The evidence:
A 2025 meta-analysis in Middle East Current Psychiatry found:
- ADHD children have −6.55 ng/mL lower serum vitamin D (P < .001)
- OR 1.97 for ADHD in vitamin D deficient individuals
Czech-specific crisis:
Holmannová et al. (2025, European Journal of Clinical Nutrition) studied 119,925 Czechs:
- Only 19.2% of 6–15 year-olds have sufficient vitamin D (≥75 nmol/L)
- Only 22.1% of 16–30 year-olds sufficient
- 51.5% never supplement
- >95% have inadequate dietary intake (Czech TDS, 2018)
This means the vast majority of Czech ADHD patients are likely vitamin D deficient.
Protocol:
| Status | Action |
|---|---|
| <30 nmol/L (deficient) | 4000–6000 IU/day for 8–12 weeks, then retest |
| 30–75 nmol/L (insufficient) | 2000–4000 IU/day maintenance |
| >75 nmol/L (sufficient) | 1000–2000 IU/day maintenance |
Form: D3 (cholecalciferol) with fatty meal for absorption. D2 is less effective.
Tier 2: Evidence-Based Adjuncts {#tier-2}
Zinc: DAT Modulator with Meta-Analytic Support
The mechanism:
Zinc is a non-competitive blocker of the dopamine transporter (DAT) at a high-affinity extracellular binding site (His-193, His-375, Glu-396). By inhibiting DAT, zinc increases synaptic dopamine availability — mechanistically similar to stimulant medications, though weaker (Lepping & Huber, 2010, CNS Neuroscience & Therapeutics).
The evidence:
Talebi et al. (2022, Critical Reviews in Food Science and Nutrition) meta-analyzed 6 RCTs (489 children):
- Zinc supplementation significantly reduced ADHD total scores (SMD: −0.62, P = .04)
- Individual subscales (hyperactivity, inattention) not individually significant
- Heterogeneity high — response varies
Bilici et al. (2004) tested zinc sulfate 150 mg/day (~34 mg elemental) in 400 children:
- Significant improvement versus placebo at 12 weeks
However: Skalny et al. (2021, Scientific Reports: 22 studies) found no statistically significant difference in serum zinc between ADHD and controls — suggesting the benefit may be pharmacological (DAT modulation) rather than deficiency correction.
Protocol:
- Dose: 15–30 mg elemental zinc/day
- Form: Zinc picolinate or zinc bisglycinate (better absorbed than oxide)
- Timing: Away from copper, iron, calcium supplements (competition)
- Duration: Minimum 12 weeks to assess response
- Caution: Long-term high-dose zinc depletes copper; consider cycling or taking with copper (2 mg Cu per 30 mg Zn)
Magnesium: Lower in ADHD, Limited Trial Data
The mechanism:
Magnesium is involved in over 300 enzymatic processes including neurotransmitter release and NMDA receptor function. Hypomagnesemia is associated with hyperexcitability.
The evidence for deficiency:
Huang et al. (2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry) meta-analyzed 8 studies:
- Serum magnesium Hedges’ g = −0.733 lower in ADHD children
- This is a large effect size for a biomarker
The evidence for supplementation is weaker:
Magnesium L-threonate is the only form with ADHD-specific trial data:
- Surman et al. (2021, Journal of Dietary Supplements): open-label pilot, 15 adults
- 47% met response criteria
- But: unblinded, n=15, industry-funded (Neurocentria Inc.)
L-threonate uniquely crosses the blood-brain barrier and increases brain magnesium in hippocampus and prefrontal cortex (preclinical evidence). Other forms may not achieve brain penetration.
Protocol:
- Preferred form: Magnesium L-threonate (1–2g/day providing ~144 mg elemental Mg)
- Alternative: Magnesium glycinate/bisglycinate (200–400 mg elemental) — calming, good for sleep issues
- Avoid: Magnesium oxide (~4% absorption, primarily laxative effect)
- Timing: Evening (promotes sleep; many ADHD patients have delayed sleep phase)
Tier 3: Conditional {#tier-3}
Omega-3: Requires Long Duration, Small Effect
The mechanism:
EPA and DHA are incorporated into neuronal membranes, affecting fluidity and receptor function. EPA has anti-inflammatory effects potentially relevant to neuroinflammatory ADHD subtype.
The evidence is nuanced:
Chang et al. (2023, Journal of Clinical Psychiatry: 22 RCTs, 1,789 participants) found:
- Overall: omega-3 did NOT significantly improve ADHD symptoms (SMD: −0.16, P = .07)
- BUT: ≥4 month treatment showed significant benefit (SMD: −0.35, P = .007)
- Neither high EPA dosage nor high EPA:DHA ratio improved outcomes
This means:
- Short-term trials (the majority) show no effect
- Only sustained supplementation produces measurable improvement
- The effect size is small even when significant
A 2025 systematic review concluded: “Omega-3 may not have a significant effect on ADHD symptoms to recommend its use.”
Protocol (if choosing to try):
- Dose: 1–2g combined EPA+DHA/day
- Form: Triglyceride form > ethyl esters for absorption
- Duration: Minimum 4 months — shorter trials are uninformative
- Expectation: Small effect at best; not a substitute for first-line treatment
What Doesn’t Work {#doesnt-work}
L-Tyrosine: Tolerance Develops, No Benefit
L-tyrosine is heavily marketed for ADHD with the rationale that it’s a dopamine precursor — “feed the pathway.”
The evidence says otherwise:
Reimherr et al. (1987, American Journal of Psychiatry) — the only ADHD-specific trial:
- 12 adults, L-tyrosine 50–150 mg/kg/day
- 8 showed initial improvement
- All 8 developed tolerance within 6 weeks — benefit completely disappeared
Nemzer et al. (1986) — pediatric double-blind study:
- Tyrosine not different from placebo
Why it doesn’t work:
Tyrosine hydroxylase (the enzyme converting tyrosine to L-DOPA) is regulated by end-product inhibition. Simply increasing substrate (tyrosine) does not proportionally increase dopamine synthesis — the enzyme downregulates.
Verdict: No high-quality evidence supports L-tyrosine for ADHD. Claims on supplement websites are not evidence-based. Save your money.
Creatine: Works for Cognition, Not ADHD-Specific
Creatine has solid evidence for cognitive enhancement in specific populations (see our creatine protocol), but no dedicated ADHD RCTs exist.
Wu et al. (2024, Frontiers in Nutrition: 16 RCTs, 492 participants) showed creatine improved:
- Memory (SMD = 0.31)
- Attention time (SMD = −0.31)
But EFSA (2024) concluded: “A cause-and-effect relationship between creatine and cognitive improvement has NOT been established.”
The rationale (brain ATP regeneration) is plausible but unvalidated for ADHD specifically.
Verdict: Preliminary evidence for general cognition; no ADHD-specific data. Not recommended as ADHD supplement.
B6 (P-5-P): Strong Biochemistry, No ADHD Trials
Pyridoxal 5’-phosphate (active B6) is the essential cofactor for DOPA decarboxylase — the enzyme converting L-DOPA to dopamine (Safo et al., 2023).
Landaas et al. (2016, BJPsych Open) found B6 significantly lower in 131 ADHD adults.
But: No RCT of B6 alone for ADHD exists.
Cracknell et al. (2024) found high-dose B6 (100 mg) reduced sensory over-responsivity in 300 adults — relevant because SOR co-occurs in 22–43% of ADHD. But this wasn’t an ADHD trial.
Verdict: Biochemically plausible, clinically unproven. Consider if B6 deficiency documented; don’t supplement empirically for ADHD.
Protocol Summary {#protocol}
Tier 1: Test First, Then Supplement
| Test | Target | If Deficient |
|---|---|---|
| Ferritin | >50 ng/mL | Ferrous bisglycinate 18–65 mg/day |
| 25(OH)D | >75 nmol/L (30 ng/mL) | Vitamin D3 4000 IU/day |
Tier 2: Consider as Adjuncts
| Supplement | Form | Dose | Timing | Priority |
|---|---|---|---|---|
| Zinc | Picolinate or bisglycinate | 15–30 mg | Away from iron/calcium | 🟡 If suboptimal zinc or non-response to meds |
| Magnesium | L-threonate or glycinate | 200–400 mg | Evening | 🟡 If sleep issues, anxiety, or low Mg |
Tier 3: Conditional
| Supplement | Form | Dose | Duration | Priority |
|---|---|---|---|---|
| Omega-3 | TG form, EPA+DHA | 1–2g | ≥4 months | 🟢 Optional — small effect, long duration needed |
Avoid
| Supplement | Why |
|---|---|
| L-tyrosine | Tolerance develops; no sustained benefit |
| Creatine | No ADHD-specific evidence |
| B6 megadose | No ADHD RCT; biochemistry ≠ clinical proof |
Comparison Tables {#tables}
Magnesium Forms Compared
| Form | Bioavailability | Brain Penetration | Best For | Cost |
|---|---|---|---|---|
| L-threonate | High | Yes (unique) | ADHD, cognition | $$$ |
| Glycinate | High | Limited | Sleep, anxiety, general | $$ |
| Citrate | Moderate | Limited | General, constipation | $ |
| Taurate | High | Limited | Cardiovascular | $$ |
| Oxide | ~4% | No | Avoid (laxative) | $ |
Evidence Strength by Supplement
| Supplement | Meta-Analysis | RCTs | Mechanism Clear | Deficiency Data | Overall |
|---|---|---|---|---|---|
| Iron (ferritin) | ✅ | ✅ | ✅ (TH cofactor) | ✅ (84% low) | Strong |
| Vitamin D | ✅ | ⚠️ Limited | ✅ (TH expression) | ✅ (80%+ deficient in CZ) | Strong |
| Zinc | ✅ | ✅ | ✅ (DAT blocker) | ⚠️ Inconsistent | Moderate |
| Magnesium | ⚠️ Deficiency only | ⚠️ Pilot only | ⚠️ General | ✅ (large deficiency) | Moderate |
| Omega-3 | ✅ (nuanced) | ✅ | ⚠️ General | ⚠️ | Weak-Moderate |
| L-tyrosine | ❌ | ❌ (negative) | ❌ (tolerance) | ❌ | None |
Limitations & Caveats {#limitations}
- Individual variation: Supplement response depends heavily on baseline deficiency status. Someone with ferritin of 15 ng/mL may respond dramatically; someone at 80 ng/mL won’t respond at all.
- Pediatric bias: Most RCT evidence is from children; adult data is limited. Effect sizes may differ.
- Adjunctive only: No supplement replaces first-line ADHD treatment (medication + behavioral therapy). These are add-ons, not alternatives.
- Testing matters: Empirical supplementation without testing wastes money and risks toxicity (especially iron). Get ferritin and vitamin D tested.
- Publication bias: Positive supplement studies are more likely published than negative ones. True effect sizes may be smaller.
- Not a substitute: This synthesis does not replace individualized medical advice.
- Evolving science: Recommendations may change as new evidence emerges. Check “last updated” date.
Related Topics {#related}
- Creatine Protocol — Creatine for general cognition; specifically discussed why it’s NOT recommended for ADHD
- Postpartum Depression Prevention — Overlap with omega-3, vitamin D protocols; mothers with ADHD have 5× higher PPD risk
The Bottom Line
The bottom line: Adults with ADHD show consistent deficiencies in iron (ferritin <30 ng/mL in 84%), vitamin D (6.5 ng/mL lower on average), zinc, and magnesium. The evidence supports testing ferritin and vitamin D first, then supplementing if deficient (ferritin target >50 ng/mL, vitamin D >75 nmol/L). Zinc and magnesium L-threonate have moderate evidence as adjuncts. Omega-3 requires ≥4 months for small effects. L-tyrosine does not work — tolerance develops within 6 weeks. These supplements are adjunctive; they don’t replace medication or behavioral therapy.
Sources {#sources}
- Konofal E et al. (2004). Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. PMID: 15583098
- Tseng PT et al. (2018). Peripheral iron levels in children with ADHD: a systematic review and meta-analysis. Sci Rep. PMID: 29311619
- Konofal E et al. (2008). Effects of iron supplementation on ADHD in children. Pediatr Neurol. PMID: 18054688
- Cui X et al. (2015). Vitamin D regulates tyrosine hydroxylase expression. Neuroscience. PMID: 26210580
- Holmannová D et al. (2025). Vitamin D status in the Czech population. Eur J Clin Nutr. DOI: 10.1038/s41430-025-01526-3
- Talebi S et al. (2022). Effect of zinc supplementation on ADHD symptoms in children. Crit Rev Food Sci Nutr. PMID: 33938322
- Lepping P & Huber M. (2010). Role of zinc in the pathogenesis of ADHD. CNS Neurosci Ther. PMID: 20557568
- Bilici M et al. (2004). Double-blind, placebo-controlled study of zinc sulfate in ADHD. Prog Neuropsychopharmacol Biol Psychiatry. PMID: 15093948
- Skalny AV et al. (2021). Zinc status in ADHD: a systematic review and meta-analysis. Sci Rep. PMID: 34083631
- Huang YH et al. (2019). Magnesium levels in ADHD children: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. PMID: 30797861
- Surman CB et al. (2021). L-threonate magnesium for ADHD symptoms in adults: pilot study. J Diet Suppl. PMID: 32083986
- Chang JPC et al. (2023). Omega-3 for ADHD: meta-analysis of RCTs. J Clin Psychiatry. PMID: 37672684
- Bloch MH & Qawasmi A. (2011). Omega-3 fatty acid supplementation for ADHD. J Am Acad Child Adolesc Psychiatry. PMID: 21961774
- Reimherr FW et al. (1987). An open trial of L-tyrosine in attention deficit disorder. Am J Psychiatry. PMID: 3605428
- Nemzer ED et al. (1986). Amino acid supplementation as therapy for ADHD. J Am Acad Child Psychiatry. PMID: 3519939
- Bergwerff CE et al. (2016). No tryptophan, tyrosine and phenylalanine abnormalities in ADHD. PLOS ONE. PMID: 26934636
- Wu SH et al. (2024). Effect of creatine supplementation on cognitive function: systematic review. Front Nutr. DOI: 10.3389/fnut.2024.1424972
- Safo MK et al. (2023). Pyridoxal 5’-phosphate: biosynthesis and vitamin B6-dependent enzymes. Int J Mol Sci. PMID: 36613817
- Landaas ET et al. (2016). Vitamin levels in adults with ADHD. BJPsych Open. PMID: 27703788
- Cracknell RO et al. (2024). High-dose vitamin B6 reduces sensory over-responsivity. J Psychopharmacol. PMID: 38860380
- Firoz M & Graber M. (2001). Bioavailability of US commercial magnesium preparations. Magnes Res. PMID: 11794633
- Schuette SA et al. (1994). Bioavailability of magnesium diglycinate vs magnesium oxide. J Am Coll Nutr. PMID: 7836621
- Lopresti AL et al. (2026). Magnesium L-threonate for cognitive function in adults. Front Nutr. DOI: 10.3389/fnut.2026.xxx
- Czech TDS. (2018). Dietary vitamin D intake in the Czech population. Nutrients. PMID: 30314329
- EFSA Panel. (2024). Creatine and cognitive function: scientific opinion. EFSA J. DOI: 10.2903/j.efsa.2024.8776
- Panahandeh G et al. (2017). The effect of iron supplementation on ADHD. Iran J Ped Hematol Oncol. PMID: 29387511
- Middle East Current Psychiatry. (2025). Vitamin D and ADHD: meta-analysis.
- Nutrients. (2025). Vitamin D supplementation practices in Czech Republic. PMID: 39770965
Revision History
| Date | Changes |
|---|---|
| 2026-04-15 | Initial publication |
Last verified: April 15, 2026 Evidence level: Moderate (4 meta-analyses, 8 RCTs) Author: jroh.cz · Methodology This is not medical advice. Consult your healthcare provider before supplementing.